Korro Bio: doses first cohort in KRRO-121 Phase 1/2 trial

What happened

• On Oct 5, 2026, Korro Bio announced that it has dosed the first cohort of participants in ANCHOR, its Phase 1/2 clinical trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. The company filed a press release as Exhibit 99.1 to the Form 8-K and incorporated it by reference.

Key details

• Trial name: ANCHOR; trial phase: Phase 1/2.
• Drug: KRRO-121, described as a GalNAc-conjugated RNA-editing oligonucleotide.
• Date of announcement and press release: Oct 5, 2026.
• The press release is filed as Exhibit 99.1 to the Form 8-K.

Why it may matter

• The filing reports Item 8.01 (other events), which covers events the company wishes to disclose outside other specific Item categories, and Item 9.01 (financial statements and exhibits), which covers exhibits filed with the report. A filing does not show why the insider traded or why the company acted.